The acquisition expands DJO’s foot and ankle business as MedShape develops a superelastic nickel-titanium shape memory alloy, as well as shape memory polymer technologies. Other technologies in the deal include devices for fracture fixation, joint fusion and soft tissue injury repair that utilize biomaterial technologies designed to improve patient outcomes.
“Based on our long-term success and deep relationships in both our prevention & recovery and recon segments, we made a strategic decision to meaningfully expand into the fast-growing foot and ankle market. We believe our acquisitions of Star, Trilliant Surgical, and now MedShape, have created a strong position in the space and will create a rapid growth platform,” DJO CEO Brady Shirley said in a news release. “MedShape’s patented technology and growing suite of foot & ankle innovations complement our existing portfolio and strengthen our key strategic imperative of superior clinical outcomes.”
MedShape’s product line opens a new market entry for bone healing and self-adapting foot and ankle implants, a market that is expected to grow and reach $1.58 billion by 2025, according to DJO.
“As the industry leader in developing shape memory technologies and successfully applying that science to foot and ankle products, we have unbounded future potential,” MedShape co-founder Ken Gall said. “We are excited to continue developing and integrating this breakthrough science to expand into other areas of orthopedics leveraging DJO’s market leadership, patient outcome focus and commitment to product innovation.” Dr. Gall will take on a new role at DJO and become the chief scientific officer for the growing reconstructive segment.”